guest ::
| Home > Publications database > P03.22.A USE OF POSITRON EMISSION TOMOGRAPHY (PET) IN PATIENTS WITH BRAIN TUMOURS AMONG EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER - BRAIN TUMOUR GROUP (EORTC-BTG) SITES |
| Home > Publications database > P03.22.A USE OF POSITRON EMISSION TOMOGRAPHY (PET) IN PATIENTS WITH BRAIN TUMOURS AMONG EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER - BRAIN TUMOUR GROUP (EORTC-BTG) SITES |
| Abstract | FZJ-2026-01534 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2025
This record in other databases: 
Please use a persistent id in citations: doi:10.1093/neuonc/noaf193.181
Abstract: AbstractBACKGROUNDData on the use of positron emission tomography (PET) among neuro-oncology centers in Europe are scarce.MATERIAL AND METHODSFrom 06/2024 to 08/2024, a cross-sectional survey among European Organization for Research and Treatment in Cancer - Brain Tumor Group (EORTC-BTG) sites was performed to gain insights into the availability and use of PET across brain tumor centers in Europe.RESULTSIn total, 312 sites were invited, and 103 replies from 20 countries were recorded. PET was available at 96/103 (93.2%) sites, and 74 of these reported PET use in patients with central nervous system neoplasms. Most frequently, PET was performed in glioma (69/74, 93.2%), followed by brain metastasis (58/74, 78.4%), meningioma (52/74, 70.3%), and CNS lymphoma (46/74, 62.2%). Amino acid PET was performed at 62/71 sites (87.3%, 3 not reported [n.r.]), and most frequently in glioma (58/59, 98.3%) and for differentiation of treatment-related changes from tumour progression (58/59, 98.3%). The prevailing amino acid tracer was [18F]FET (45/59, 76.3%), followed by [18F]FDOPA (22/59, 37.3%) and [11C]methionine (15/59, 25.4%). Dynamic acquisition protocols for amino acid PET were used by 35/59 (59.3%) sites. Somatostatin receptor (SSTR) PET was applied at 50/68 sites (73.5%, 6 n.r.) and mainly in meningioma (48/49, 98.0%) and for patient selection before radioligand therapy (41/49, 83.7%) as well as for target volume definition in radiotherapy (33/49, 67.3%). PET was reportedly covered by statutory health insurance at 46/59 (78.0%) centres for amino acid PET and 33/49 (67.3%) for SSTR PET. Reasons for not using PET in clinical routine included limited availability of tracers (14/29, 48.3%), high cost (11/29, 37.9%), and PET not perceived necessary (8/29, 27.6%).CONCLUSIONPET is widely used within the EORTC BTG network, underscoring the feasibility of PET-based clinical trial endpoints which support the generation of evidence for further implementation in clinical routine. As our survey may be prone to selection and non-response bias, a comprehensive analysis of PET application patterns would be desirable.
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 15 ; JCR ; Nationallizenz
; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
